Ahl Partners Llp Lowered Its Colgate Palmolive Co (CL) Holding; Alkermes PLC (ALKS)’s Sentiment Is 0.75

March 20, 2018 - By Hazel Jackson

Ahl Partners Llp decreased Colgate Palmolive Co (CL) stake by 88.3% reported in 2017Q3 SEC filing. Ahl Partners Llp sold 123,143 shares as Colgate Palmolive Co (CL)’s stock rose 3.95%. The Ahl Partners Llp holds 16,312 shares with $1.19M value, down from 139,455 last quarter. Colgate Palmolive Co now has $61.00 billion valuation. The stock decreased 0.53% or $0.37 during the last trading session, reaching $69.69. About 2.40 million shares traded. Colgate-Palmolive Company (NYSE:CL) has risen 6.23% since March 20, 2017 and is uptrending. It has underperformed by 10.47% the S&P500.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $9.42 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

The stock decreased 0.23% or $0.14 during the last trading session, reaching $60.32. About 321,797 shares traded. Alkermes plc (ALKS) has risen 47.50% since March 20, 2017 and is uptrending. It has outperformed by 30.80% the S&P500.

Ratings analysis reveals 100% of Alkermes’s analysts are positive. Out of 3 Wall Street analysts rating Alkermes, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $70.0 while the high is $70.0. The stock’s average target of $70 is 16.05% above today’s ($60.32) share price. ALKS was included in 3 notes of analysts from October 21, 2016. The stock of Alkermes plc (NASDAQ:ALKS) earned “Overweight” rating by JP Morgan on Friday, October 21. The stock has “Outperform” rating by Leerink Swann on Friday, October 21. Jefferies maintained the shares of ALKS in report on Friday, October 21 with “Buy” rating.

Meditor Group Ltd holds 7.95% of its portfolio in Alkermes plc for 1.03 million shares. Opus Point Partners Management Llc owns 48,244 shares or 2.2% of their US portfolio. Moreover, Roanoke Asset Management Corp Ny has 1.64% invested in the company for 68,621 shares. The California-based Kelly Lawrence W & Associates Inc Ca has invested 1.24% in the stock. Twin Focus Capital Partners Llc, a Massachusetts-based fund reported 40,000 shares.

Since December 13, 2017, it had 0 insider purchases, and 19 selling transactions for $31.54 million activity. 44,418 shares were sold by MOISON FRANCK J, worth $3.10M. 902 Colgate-Palmolive Company (NYSE:CL) shares with value of $68,390 were sold by Daniels Jennifer. $292,026 worth of Colgate-Palmolive Company (NYSE:CL) was sold by Skala Justin. On Tuesday, February 20 COOK IAN M sold $1.47 million worth of Colgate-Palmolive Company (NYSE:CL) or 20,891 shares. $346,581 worth of Colgate-Palmolive Company (NYSE:CL) shares were sold by HANCOCK ELLEN M. CAHILL JOHN T also sold $489,696 worth of Colgate-Palmolive Company (NYSE:CL) on Tuesday, February 13. Shares for $2.58 million were sold by JAKOBSEN HENNING I on Monday, February 5.

Among 25 analysts covering Colgate-Palmolive (NYSE:CL), 6 have Buy rating, 1 Sell and 18 Hold. Therefore 24% are positive. Colgate-Palmolive had 66 analyst reports since July 21, 2015 according to SRatingsIntel. UBS maintained the stock with “Neutral” rating in Friday, October 28 report. As per Friday, March 24, the company rating was maintained by RBC Capital Markets. Stifel Nicolaus maintained the shares of CL in report on Monday, September 18 with “Hold” rating. The stock has “Buy” rating by Citigroup on Friday, July 29. The rating was maintained by B. Riley & Co on Friday, October 28 with “Neutral”. BNP Paribas upgraded the shares of CL in report on Friday, January 15 to “Outperform” rating. The rating was upgraded by SunTrust to “Buy” on Wednesday, October 11. BNP Paribas downgraded the stock to “Neutral” rating in Friday, July 29 report. The firm has “Hold” rating by KeyBanc Capital Markets given on Wednesday, November 22. The stock has “Buy” rating by Bank of America on Monday, September 12.

Investors sentiment decreased to 0.87 in 2017 Q3. Its down 0.03, from 0.9 in 2017Q2. It dropped, as 52 investors sold CL shares while 437 reduced holdings. 92 funds opened positions while 350 raised stakes. 617.24 million shares or 0.04% less from 617.46 million shares in 2017Q2 were reported. Apg Asset Mgmt Nv owns 4.07M shares. Sandy Spring National Bank & Trust accumulated 33,891 shares or 0.24% of the stock. Wesbanco Bank invested 0.1% of its portfolio in Colgate-Palmolive Company (NYSE:CL). Chatham Capital owns 0.72% invested in Colgate-Palmolive Company (NYSE:CL) for 35,010 shares. Hendley And Com Inc reported 0.25% stake. Sumitomo Mitsui Asset Mngmt has invested 0.07% in Colgate-Palmolive Company (NYSE:CL). Endurance Wealth Mngmt Inc owns 37,507 shares. Guggenheim Ltd Liability holds 0.15% or 876,137 shares in its portfolio. Covington Invest Advsrs stated it has 6,670 shares. Checchi Cap Advisers Ltd Liability Corp reported 0.05% in Colgate-Palmolive Company (NYSE:CL). Winfield Assocs owns 190 shares for 0.01% of their portfolio. Rand Wealth Ltd Company has 11,522 shares. Moreover, Cue Gp has 0.25% invested in Colgate-Palmolive Company (NYSE:CL) for 4,854 shares. American Beacon Advsrs accumulated 1.22% or 1,399 shares. Paradigm Cap Inc New York reported 0.54% of its portfolio in Colgate-Palmolive Company (NYSE:CL).

Ahl Partners Llp increased Logmein Inc (NASDAQ:LOGM) stake by 7,383 shares to 14,076 valued at $1.55 million in 2017Q3. It also upped Paccar Inc (NASDAQ:PCAR) stake by 8,171 shares and now owns 18,130 shares. Regal Beloit Corp (NYSE:RBC) was raised too.

Analysts await Colgate-Palmolive Company (NYSE:CL) to report earnings on April, 27. They expect $0.74 EPS, up 10.45% or $0.07 from last year’s $0.67 per share. CL’s profit will be $647.75 million for 23.54 P/E if the $0.74 EPS becomes a reality. After $0.75 actual EPS reported by Colgate-Palmolive Company for the previous quarter, Wall Street now forecasts -1.33% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: